Clinical Trials and Data Readouts - Interim data readout for ARTISTRY-7, a phase 3 trial evaluating nemvaleukin in combination with pembrolizumab for platinum-resistant ovarian cancer (PROC), expected in late Q1/early Q2 2025, with 75% of overall survival (OS) events reached for interim analysis [3][6] - Top-line data readout for ARTISTRY-6, Cohort 2, evaluating nemvaleukin monotherapy for mucosal melanoma, expected in Q2 2025, with a target response rate of 25% [6][7] - Preliminary data readout for less-frequent intravenous (LFIV) dosing of nemvaleukin monotherapy in cutaneous melanoma expected in 1H 2025, with patient enrollment complete [3][13] - Preliminary data readout for LFIV dosing of nemvaleukin in combination with pembrolizumab for cutaneous melanoma expected in 2H 2025 [13] Pipeline Expansion and Development Candidates - Mural nominated two new development candidates: MURA-8518, a half-life extended, binding protein-resistant IL-18, and MURA-7012, targeted split sub-units of IL-12 [3][4] - MURA-8518 aims to overcome native IL-18 limitations by eliminating binding to IL-18BP and extending half-life, with an IND submission expected in Q4 2025 [4][11] - MURA-7012 is designed to limit systemic exposure by delivering IL-12 preferentially to the tumor microenvironment, with preclinical studies showing reduced serum toxicity [12] Financial and Operational Updates - Mural extended its cash runway projection into Q1 2026 through operational efficiencies [3][5] - The company has transformed into a robust organization with multiple expected data catalysts since becoming independent [5] Regulatory and Strategic Milestones - If ARTISTRY-7 interim analysis meets the hazard ratio threshold (0.727, 27.3% reduction in risk of death), Mural plans to submit a Biologics License Application (BLA) for nemvaleukin in combination with pembrolizumab for PROC in 2025 [6] - Final OS results for ARTISTRY-7 expected in Q2 2026, with a maximum hazard ratio for success of 0.788 (21.2% reduction in risk of death) [6] - Nemvaleukin has been granted Orphan Drug Designation by the FDA for mucosal melanoma [6] Company Overview - Mural Oncology is a clinical-stage immuno-oncology company developing engineered cytokine therapies for cancer, with a focus on platinum-resistant ovarian cancer and mucosal melanoma [9] - The company leverages its protein engineering platform to develop cytokine-based immunotherapies, aiming to improve clinical outcomes for cancer patients [9]
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts